Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Umut Cakıroglu"'
Publikováno v:
Turkish Journal of Hematology, Vol 41, Iss 1, Pp 57-58 (2024)
Externí odkaz:
https://doaj.org/article/550c430e27d743d0bfeb5e5deba3b531
Autor:
Atike Gökçen Demiray, Aydın Demiray, Arzu Yaren, Burcu Taşköylü, Gamze Gököz Doğu, Serkan Değirmencioğlu, Umut Çakıroğlu, Nail Özhan, Canan Karan, Burçin Çakan Demirel, Tolga Doğan, Melek Özdemir
Publikováno v:
The Turkish Journal of Gastroenterology, Vol 33, Iss 8, Pp 696-703 (2022)
Externí odkaz:
https://doaj.org/article/161a9eb498124b999615efef94d858c9
Autor:
Birol Ocak, Ahmet Bilgehan Sahin, Ismail Ertürk, Mustafa Korkmaz, Dilek Erdem, Umut Cakıroglu, Mustafa Karaca, Ahmet Dirican, Omer Fatih Olmez, Sabin Goktas Aydın, Ali Gökyer, Ahmet Kücükarda, Ahmet Gülmez, Perran Fulden Yumuk, Nazim Can Demircan, Abdilkerim Oyman, Teoman Sakalar, Fatih Karatas, Hacer Demir, Ayse Irem Yasin, Adem Deligonul, Bahar Dakiki, Mehmet Refik Goktug, Okan Avcı, Seher Yildiz Tacar, Nazım Serdar Turhal, Gülhan Ipek Deniz, Turgut Kacan, Erdem Cubukcu, Türkkan Evrensel
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5195-5205 (2024)
Background: This study aimed to investigate the effect of cytoreductive nephrectomy (CN) on the survival outcomes of nivolumab used as a subsequent therapy after the failure of at least one anti-vascular endothelial growth factor (VEGF) agent in pati
Externí odkaz:
https://doaj.org/article/e3b91b5047204acf948136cd657f8dec
Autor:
Birol Ocak, Ahmet Bilgehan Sahin, Ismail Ertürk, Mustafa Korkmaz, Dilek Erdem, Umut Cakıroglu, Mustafa Karaca, Ahmet Dirican, Omer Fatih Olmez, Sabin Göktaş Aydın, Ali Gökyer, Ahmet Küçükarda, Ahmet Gülmez, Perran Fulden Yumuk, Nazim Can Demircan, Abdilkerim Oyman, Teoman Sakalar, Fatih Karataş, Hacer Demir, Ayse Irem Yasin, Adem Deligönül, Bahar Dakiki, Mehmet Refik Goktug, Okan Avcı, Seher Yildiz Tacar, Nazım Serdar Turhal, Gulhan Ipek Deniz, Turgut Kacan, Erdem Cubukcu, Türkkan Evrensel
Renal cell carcinoma is the fourteenth most common cancer in the world with a male to female ratio of 2:1, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Nivolumab is preferred as subsequent therapy in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e5a15870b5d76209b99a5b795b3e4bc
https://doi.org/10.21203/rs.3.rs-1693977/v1
https://doi.org/10.21203/rs.3.rs-1693977/v1